Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Understanding Patients’ Journeys Prior to Initiating Calcitonin Gene-related Peptide Monoclonal Antibody for Migraine Prevention in the United States
Headache
P8 - Poster Session 8 (5:30 PM-6:30 PM)
12-008

Although migraine is associated with several disabling symptoms, many patients are reluctant to initiate pharmacological treatment. Understanding the path in seeking care may highlight opportunities for intervention.

To describe experience with migraine and factors influencing the decision to seek treatment in a cohort of patients in the US initiating galcanezumab for migraine prevention.

We conducted a cross-sectional, self-reported, online survey among 500 patients enrolled in the galcanezumab Patient Support Program between Jul-Dec 2022. Patients were ≥18 years of age, diagnosed with episodic (n=250) or chronic (n=250) migraine, and prescribed galcanezumab ≤6 months prior to survey completion. Individual questions and validated questionnaires were used to collect insights on patients’ experience with migraine and interaction with healthcare professionals (HCPs) prior to initiating galcanezumab. All analyses were descriptive.

Average time since first migraine symptom was 18.1 years and on average patients visited four HCPs before receiving a migraine diagnosis. Prior to diagnosis, about a third of patients were reluctant to seek professional help for migraine due to a previous unhelpful experience (32.1%)/due to thinking that a physician could not do anything more for their migraine (32.1%)/that a physician would not take them seriously (32.1%). Few patients (18.3%) believed that migraine attacks were due to factors such as stress/diet they could control. Most patients decided to seek professional help for migraine due to increasing frequency (81.0%)/intensity (71.7%) of migraine attacks. Patients reported that the most common explanation the HCP provided for causes of migraine was stress/anxiety/depression (41.6%). Over a third (36.0%) indicated that their HCPs’ explanation that migraine has no cause was aligned with what they had previously thought.

Patients’ decisions regarding migraine prevention are influenced by past experiences involving triggers and interactions with HCPs. Increased awareness of patients’ journey to treatment may help address misinformation and improve migraine care.

Authors/Disclosures
Lars Viktrup
PRESENTER
No disclosure on file
Maurice B. Vincent, MD, PhD (Eli Lilly and Company) Prof. Vincent has received personal compensation for serving as an employee of Eli Lilly and Company. Prof. Vincent has stock in Eli Lilly and Company.
Margaret Hoyt, PhD (Eli Lilly and Co.) Dr. Hoyt has received personal compensation for serving as an employee of Eli Lilly and Co.. Dr. Hoyt has stock in Eli Lilly and Co..
William Lenderking (Evidera) No disclosure on file
Lucinda Hetherington (Eviderda) No disclosure on file
Dustin Ruff Dustin Ruff has received personal compensation for serving as an employee of Eli Lilly and Company. Dustin Ruff has stock in Eli Lilly and Company.
Gilwan Kim (Eli Lilly) No disclosure on file